BROOMFIELD, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the issuance of three additional patents. The U.S. Patent & Trademark Office (PTO) granted two new patents which provide intellectual property protection for methods relating to the Company’s products and technology. In addition, the European Patent Office granted to Biodesix a patent providing coverage for the Company’s product VeriStrat®, for the selection of patients for drug therapy. VeriStrat is a serum proteomic test currently available in the United States to help physicians guide therapy for patients with advanced lung cancer.
